Borrelia burgdorferi, and occasionally Borrelia mayonii, are the bacteria that cause Lyme disease. The infection is spread to humans by the bite of infected black-legged insects. The most common symptoms are fever, headaches, fatigue, and an unusual skin rash called Erythema Migratoris. The infection can spread to the nervous system, joints, and heart if left untreated. Lyme disease can be diagnosed by looking at symptoms and physical signs (e.g., rash) as well as the possibility of tick exposure. If laboratory testing is done correctly and with valid methods, it can be very helpful. Lyme disease can usually be treated with antibiotics within a few weeks. If the disease is not treated, it can cause serious complications, including damage to the central nervous system, joints, and heart. Many diagnostic tests can be used to detect Lyme disease. These include the serological test (PCR), immunofluorescence, IFA, lymphocyte transformation test (LYM), and urine antigen testing. Two methods can be used by healthcare organizations like the CDC to detect these antibodies or immunizers to confirm a diagnosis. To diagnose Borrelia IgM or IgG antibodies, the first method is to use an enzyme immunoassay (EIA), or immunofluorescence(IFA) method. This diagnosis is meant to be sensitive to detect Lyme disease cases as many times as possible. Even if the results are positive for similar bacteria, such as syphilis or tick-borne diseases, they may still be positive. After the initial test with positive or indeterminate results, a second diagnosis is recommended. This is known as a Western Blot, which detects specific antibodies against multiple antigens to confirm the results. The market is driven by the rising prevalence of Lyme disease and increased government focus on improving healthcare facilities. New Lyme disease diagnostic tests are also being developed. The market is severely restricted by a lack of knowledge and inefficiency in Lyme Disease Testing. The market will also benefit from the increased interest of key players in R D for Lyme disease diagnosis. Many researchers are currently working to develop a rapid, point-of-care Lyme diagnostic using lateral flow technology. The identification and definition of metabolic biomarkers and biosignatures are key to enhanced diagnostics. These studies will help to identify Lyme disease earlier, to better diagnose it, to accurately stage the disease, and to show signs of treatment success. This will fuel the Lyme disease diagnostics market.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Lyme Disease Diagnostics Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.
According to the research study conducted by FutureWise research analysts, the Lyme Disease Diagnostics Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.